Connect with us

World News

Plan to boost Swiss firms’ global liability fails in referendum | Switzerland

Published

on

Switzerland rejects extending corporate liability over rights abuses and environmental harm caused abroad.

A proposal that could have stiffened penalties against companies based in Switzerland if they violate human rights or harm the environment abroad has failed in a Swiss referendum.

The initiative to change the constitution by the Responsible Business Initiative (RBI) won a narrow majority of votes on Sunday, with 50.7 percent backing it and 49.3 percent against, but failed because most of the country’s 23 cantons, or states – three of which are split in half – came out against it.

Under Switzerland’s system of direct democracy, which gives voters a direct say several times each year on a variety of issues, proposals need a majority both of votes cast and of cantons to pass.

It only achieved a majority in eight and a half cantons – including the four major cities of Zurich, Geneva, Basel and the capital, Bern – with the rest voting against.

The federal government opposed the plan championed by left-leaning groups and some big civil society organisations, asserting that it went too far.

The measure could have made large Switzerland-based companies liable in the country’s courts for their flawed operations or those of their subsidiaries and subcontractors in foreign nations, unless they were able to show that they conducted proper due diligence beforehand.

The rejection by voters automatically activated the government’s counter-proposal, which also requires companies to report on rights, environmental protections and corruption issues – but without being liable for violations.

Polarised campaign

The initiative was launched by an alliance of 130 non-governmental organisations and had the backing of trade unions and church groups.

Supporters of the rejected initiative had plastered Swiss towns and cities with posters highlighting environmental degradation and human suffering caused by Swiss companies.

Campaigners also underscored how pesticides long banned in Switzerland are still sold by agrochemicals giant Syngenta in developing countries, and deplored small-particle pollution spewed from a cement plant owned by LafargeHolcim in Nigeria.

The government and multinationals said the proposal went too far [Fabrice COFFRINI/AFP]

The Swiss business community, along with the government and parliament, argued that the proposed constitutional amendments could have been detrimental for all Swiss companies, not just those that behave badly.

Multinational companies are important drivers of the Swiss economy, which at the end of 2018 counted close to 29,000 such corporations, accounting for more than a quarter of all jobs in the country, according to official statistics.

Businesses and employer organisations voiced particular concern over a provision that would have made Swiss-based businesses liable for abuses committed by subsidiaries unless they could prove they had done required due diligence.

While backers of the rejected initiative acknowledged that most companies respect rights and environmental protections, they insisted that voluntary measures were not enough to bring the rest in line.

Another measure that would have banned the financing by the Swiss national bank or pension funds of any weapons for export, from handguns to assault rifles to tanks, also failed on Sunday, with a majority of both voters and cantons opposing it.



Source link

World News

COVID: How has the UK managed to master the vaccine roll-out? | Coronavirus pandemic News

Published

on

London, United Kingdom – When Ayesha Sharieff, a general practitioner in a south London surgery, administered the first COVID vaccines to her patients earlier this month, she was overjoyed.

“It was the best afternoon I’ve spent for a long time,” said Sharieff, who has been a doctor for 20 years. “After all these tough times we’ve been through recently, it was such a pleasure. I wanted to jump on top of my car and honk the horn.”

Each day, Sharieff and her team vaccinate up to 300 patients, currently focusing on elderly people from the area’s diverse urban population as a priority, as part of the United Kingdom’s rapid vaccine roll-out.

“I recently vaccinated a Caribbean nurse working in infectious diseases who must have been 88,” said Sharieff. “It just felt like such an honour to be doing that for her. I had tears in my eyes.”

The UK has earned cautious early praise for its vaccine roll-out, which has seen it produce double the number of vaccinations per person per day of any other European country.

This marks a significant turnaround because with the highest COVID-19 death toll in Europe, the UK government faces high levels of criticism for failing to contain the virus.

The UK became the first Western country to license a COVID-19 vaccine on December 2 when the medicines regulator approved the Pfizer-BioNTech jab [File: Phil Noble/Reuters]

More than six million people in the UK have received a first dose of a COVID-19 vaccine to date, as part of the largest vaccination programme in British history. The National Health Service (NHS) has vaccinated more than half of those aged 80 and over and more than half of elderly care home residents, both considered priorities, according to the Department of Health and Social Care.

Once those priorities have been treated, the UK will offer the vaccine to everyone over 50 and then everyone aged over 18.

‘Flexible, scalable system’

British Prime Minister Boris Johnson’s government has said it plans to offer a first dose of vaccine to every adult in Britain, who make up 51 million of its total 67.5 million population, by September.

It will soon begin a trial of 24-hour injections as it continues to add more vaccination sites to increase the pace of delivery.

Good logistics planning and significant financial investment have underpinned the early positive vaccination numbers, according to Sarah Schiffling, a supply chains expert at Liverpool John Moores University.

“We can’t underestimate the fact the UK is devoting nearly £12 billion to the purchase, manufacture and roll-out of the vaccine,” she told Al Jazeera. “But the UK is seeing the benefit of having a coordinated approach. It’s started out really well and gotten up to quite a volume of patients vaccinated very quickly and that is very promising.”

Schiffling believes the centralised nature of the NHS as well the UK’s “far-reaching delivery network” – which spans from local GPs to mass vaccination centres – has also played a key role. “It’s a flexible, scalable system and that’s been working really well so far,” she explained.

The NHS, unlike some countries that have a federal approach, has departments already in place for bulk purchasing, says Schiffling, and the UK invested quickly into materials such as syringes that are now in high demand.

“One system can work along the supply chain, and that’s worked to the UK’s advantage here,” she said.

UK adopts first dose strategy

The UK became the first Western country to license a COVID-19 vaccine on December 2 when the medicines regulator approved the Pfizer-BioNTech jab. Since then, it has also approved vaccines produced by Oxford-AstraZeneca and Moderna, but doses of the latter are not expected for months.

But unlike other nations, the UK has decided to increase the time between vaccine doses given to people from 21 days to up to 12 weeks, a decision that is thought to mean more people will get their first dose more quickly.

“The UK has prioritised getting people the first doses,” said Mark Jit, a professor of vaccine epidemiology at the London School of Hygiene and Tropical Medicine. “This has enabled more people to be vaccinated quickly. From what we know about vaccines, the first dose gives quite good protection, especially with the Astra-Zeneca vaccine. It’s not that the second dose will be dropped entirely.”

Professor Jit says the UK’s history of previous successful campaigns has also helped the rapid roll-out.

“The UK has an advantage because it has a long history of successful vaccine introductions,” he said, pointing to the introduction of the Shingles vaccine to adults in 2013, the HPV vaccine for adolescents in 2008 and national flu campaigns. “Part of it is also good communication, so there is good public confidence in vaccines.”

Johnson poses for a photograph with a vial of the Oxford University-AstraZeneca COVID-19 candidate vaccine in Wrexham, Wales, on November 30, 2020 [File: Paul Ellis/Pool via Reuters]

But Jit added that while success in the UK’s vaccine roll-out is good news, the issue will persist while all countries still need vaccine supplies.

“This is a global issue and the pandemic won’t be solved until we address those worldwide concerns,” he said.

With England in a third national lockdown since January 2 after a highly transmissible variant helped push the number of people hospitalised with COVID-19 to record highs, for some, vaccination can’t come any sooner.

The UK is now rapidly approaching 100,000 coronavirus-related deaths, marking the worst death toll in Europe and the fifth-highest number worldwide, and some 50,000 health workers are off work due to COVID-19 infections and exposure quarantines.

“This vaccine roll-out has been one of the most uplifting things in my career,” said Sharieff, the GP. “But as it continues we will have to vaccinate larger, more diverse patient groups. We need to make sure everyone is protected equally.”



Source link

Continue Reading
Advertisement

Top Stories